KM Research Hub
← 返回论文库
待处理 入排:待复核 图源:待检查 入排置信度 0.00

Impact of Neoadjuvant Carboplatin in Early-Stage Triple-Negative Breast Cancer: A Pooled Analysis of the BrighTNess, Cancer and Leukemia Group B 40603 (Alliance), and GeparSixto Clinical Trials.

Brooke M Felsheim, Jens Huober, Lisa A Carey, Valentina Nekljudova, Thomas Karn, Sara M Tolaney, Andreas Schneeweiss, Michael Untch, Christoph Salat, Charles S Kuzma, Aranzazu Fernandez-Martinez, Sivaramakrishna Rachakonda, Jose J Ponce-Lorenzo, Dirk-Michael Zahm, Rama Suresh, Daniel G Stover, Priya Rastogi, Maren Darsow, Diana E Lake, Hope S Rugo, Joyce O'Shaughnessy, Mehra Golshan, Adam D Pfefferle, William M Sikov, Otto Metzger, Carsten Denkert, Charles E Geyer, Charles M Perou, Sibylle Loibl

JCO Oncol Adv 3(4) e2600101

PMID42992319
PMCIDPMC13739452
DOI10.1200/oa-26-00101
发表日期2026-11-06
入排依据:未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。
摘要

摘要

PURPOSE: To better characterize the therapeutic benefits of the addition of carboplatin to anthracycline- and taxane-based neoadjuvant chemotherapy (NACT) in early-stage triple-negative breast cancer (TNBC), we performed a pooled analysis of three randomized clinical trials: BrighTNess (NCT02032277), CALGB 40603 (NCT00861705), and GeparSixto (NCT01426880). METHODS: We evaluated the impact of the addition of carboplatin to NACT on pathologic complete response (pCR) rates, event-free survival (EFS), and overall survival (OS) across a combined total of 1,084 patients. We additionally looked for associations of outcome by germline BRCA1 and BRCA2 (gBRCA) mutation status, eight gene expression signatures, and molecular subtypes (PAM50, MDACC/BCM). RESULTS: In the pooled dataset, the addition of carboplatin to NACT was associated with a higher pCR rate (odds ratio = 1.89, 95% confidence interval [CI] = 1.41-2.55, p < 0.001) and improved EFS (hazard ratio = 0.71, 95% CI = 0.54-0.93, p = 0.01), but not OS. In patients with gBRCA mutations (n = 137), we found that the addition of carboplatin conveys a significant EFS benefit but had no significant association with pCR rate or OS. We found six immune gene expression signatures that were significantly associated with a higher pCR rate and four that were significantly associated with improved EFS and OS. Additionally, we found that the PAM50 luminal and MDACC/BCM LAR molecular subtypes were significantly associated with lower pCR rates in the combined dataset. CONCLUSION: Our findings support the recent addition of carboplatin to NACT within the standard of care treatment of stage II-III TNBC and emphasize the importance of the TNBC immune microenvironment to patient outcomes.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。